Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1493-1498

  Wallin, Åsa ^a,b   Svanvik, Joar ^a   Holmlund, Birgitta ^a   Ferreud, Lillianne ^a   Sun, Xiao Feng ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Colon cancer cell lines; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE; PROTEIN BAX; SURVIVIN; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIMED DRUG RELEASE; WESTERN BLOTTING; CELL CULTURE; CELL PROLIFERATION; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; METABOLISM; METASTASIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FLOW CYTOMETRY; G2 PHASE; HUMANS; IMMUNOENZYME TECHNIQUES; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; S PHASE; TUMOR CELLS, CULTURED;

EID: 48849114378     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA and Houghton PJ: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 4: 743-753, 1998.
2. Wall ME, Wani MC, Cook CE, Plamer KH, MacPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
3. Creemers GJ, Lund B and Verweij J: Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20: 73-96, 1994.
4. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK and Kingsbury WD: Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720, 1989.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
6. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
7. Ricci MS and Zong WX: Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11: 342-357, 2006.
8. Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, Zeitz M and Hanski C: Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 25: 165-175, 2006.
9. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837, 2004.
10. Brady HJ and Gil-Gomez G: Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol 30: 647-650, 1998.
11. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
12. Morikawa K, Walker SM, Nakajima. M, Pathak S, Jessup JM and Fidler IJ: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48: 6863-6871, 1988.
13. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
14. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
15. Ueno M, Nonaka S, Yamazaki R, Deguchi N and Murai M: SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol 42: 390-397, 2002.
16. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M and Schwartz GK: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 7: 4209-4219, 2001.
17. Tse AN and Schwartz GK: Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 64: 6635-6644, 2004.
18. te Poele RH and Joel SP: Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer 81: 1285-1293, 1999.
19. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
20. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR, Zeitz M and Hanski C: Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101: 23-31, 2002.
21. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M and Kohno K: Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19: 6194-6202, 2000.
22. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
23. Husain I, Mohler JL, Seigler HF and Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546, 1994.
24. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM and Boven E: CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 70: 335-340, 1997.
25. Kirkin V, Joos S and Zornig M: The role of Bc1-2 family members in tumorigenesis. Biochim Biophys Acta 1644: 229-249, 2004.
26. Guo B, Cao S, Toth K, Azrak RG and Rustum YM: Over-expression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 6: 718-724, 2000.
27. Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M and Zhang W: Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 16: 1587-1591, 1998.
28. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.